Decision-making for and impact of early immunomodulatory treatment: The Austrian Clinically Isolated Syndrome Study (ACISS)

European Journal of Neurology

Volumn 17, Issue 6, 2010, Pages 852-860

  Fazekas, F ^a   Baumhackl, U ^b   Berger, T ^c   Deisenhammer, F ^c   Fuchs, S ^a   Kristoferitsch, W ^d   Ladurner, G ^e   Soukop, W ^f   Wimmer, G ^g   Vass, K ^h  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Specialist in Neurology and Psychiatry   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Department of Neurology SMZ Ost Donauspital ^*  (Austria)

^e Christian Doppler Klinik   (Austria)

^f Specialist in Neurology and Psychiatry   (Austria)

^g BIOGEN   (United States)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinically isolated syndrome; Disease modifying treatment; Immunomodulatory treatment; Multiple sclerosis; Patient management; T2 lesion; Visual analogue scale

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; IMMUNOLOGIC FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; AUSTRIA; CLINICAL FEATURE; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DRUG INDICATION; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; PRIORITY JOURNAL; BRAIN; CLINICAL PRACTICE; CLINICAL TRIAL; DECISION MAKING; DEMYELINATING DISEASES; MULTICENTER STUDY; PAIN MEASUREMENT; PATHOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; AUSTRIA; BRAIN; DECISION MAKING; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PAIN MEASUREMENT; PHYSICIAN'S PRACTICE PATTERNS;

EID: 77952522947     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02943.x     Document Type: Article

References (22)

1. Polman C, Reingold S, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005 58 : 840 846. (Pubitemid 41746873)
2. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008 14 : 1157 1174.
3. Jacobs L, Beck R, Simon J, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000 343 : 898 904.
4. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 357 : 1576 1582. (Pubitemid 32488815)
5. Kappos L, Polman C, Freedman M, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 67 : 1242 1249. (Pubitemid 44563835)
6. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double blind, placebo-controlled trial. Lancet 2009 374 : 1503 1511.
7. Kinkel R, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006 66 : 678 684. (Pubitemid 43739821)
8. Kappos L, Freedman M, Polman C, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 370 : 389 397. (Pubitemid 47189673)
9. Tintoré M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006 67 : 968 972. (Pubitemid 44454586)
10. Fisniku L, Brex P, Altmann D, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008 131 : 808 817. (Pubitemid 351294716)
11. O'Connor P, CHAMPS Study Group. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 2003 25 : 2865 2874. (Pubitemid 37510595)
12. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. J Neurol 2004 251 : 1329 1339.
13. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka K, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008 255 : 1449 1463.
14. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 : 1444 1452. (Pubitemid 14237132)
15. McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001 50 : 121 127.
16. Baumhackl U, Eibl G, Ganzinger U, et al. Prevalence of multiple sclerosis in Austria. Results of a nationwide survey. Neuroepidemiology 2002 21 : 226 234. (Pubitemid 35002304)
17. Zivadinov R, Iona L, Monti-Bragadin L, et al. The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology 2003 22 : 65 74. (Pubitemid 36131978)
18. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P. Escalating immunomodulatory therapy of multiple sclerosis : update (September 2006). Article in German. Nervenarzt 2006 77 : 1506 1518. (Pubitemid 44950149)
19. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006 67 : 944 953. (Pubitemid 44454583)
20. O'Riordan J, Thompson A, Kingsley D, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10 year foll-up. Brain 1998 121 : 495 503. (Pubitemid 28116346)
21. Miller DH, Filippi M, Fazekas F, et al. The role of MRI within diagnostic criteria for multiple sclerosis: a critique. Ann Neurol 2004 56 : 273 278. (Pubitemid 39037922)
22. Tintoré M, Rovira A, Río J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008 70 : 1079 1083. (Pubitemid 351464763)